Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Amyloidosis and protein folding.

Kagan BL.

Science. 2005 Jan 7;307(5706):42-3; author reply 42-3. No abstract available.

PMID:
15641174
2.

[Amyloid fibril formation of beta 2-microglobulin].

Goto Y, Hoshino M.

Tanpakushitsu Kakusan Koso. 2002 May;47(6):663-9. Review. Japanese. No abstract available.

PMID:
11995332
3.

Deposition diseases and 3D domain swapping.

Bennett MJ, Sawaya MR, Eisenberg D.

Structure. 2006 May;14(5):811-24. Review.

4.

Misfolded proteins and human diseases.

Nayeem MS, Khan RH.

Protein Pept Lett. 2004 Dec;11(6):593-600. Review.

PMID:
15579130
5.
6.

Protein chemistry. In the footsteps of alchemists.

Dobson CM.

Science. 2004 May 28;304(5675):1259-62. No abstract available.

PMID:
15166354
7.

Metastable, partially folded states in the productive folding and in the misfolding and amyloid aggregation of proteins.

Ferreira ST, De Felice FG, Chapeaurouge A.

Cell Biochem Biophys. 2006;44(3):539-48. Review.

PMID:
16679542
8.

Renal amyloidosis (part I).

Ferrario F, Rastaldi MP.

J Nephrol. 2006 Mar-Apr;19(2):123-5.

PMID:
16736407
9.

AL 366--a glycosylated protein of kappa 1b origin in a patient with systemic amyloidosis of predominantly non-parenchymatous distribution.

Samdal IA, Sletten K, Olsen KE, Westermark P.

Amyloid. 2001 Jun;8(2):111-4. No abstract available.

PMID:
11409032
10.

Molecular mechanisms of amyloidosis.

Merlini G, Bellotti V.

N Engl J Med. 2003 Aug 7;349(6):583-96. Review. No abstract available.

PMID:
12904524
11.

Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses.

Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ.

Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):587-96. Review.

PMID:
16266291
12.

Lambda II immunoglobulin light chain protein in primary localized rectal amyloidosis.

Zaky ZS, Liepnieks JJ, Rex DK, Cummings OW, Benson MD.

Amyloid. 2007 Dec;14(4):299-304.

PMID:
17968691
13.
14.

Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis.

Glabe CG, Kayed R.

Neurology. 2006 Jan 24;66(2 Suppl 1):S74-8. Review.

PMID:
16432151
15.

The resolution of amyloid substance.

Wegelius O.

Acta Med Scand. 1982;212(5):273-5. No abstract available.

PMID:
7180576
16.

An accidental breach of a protein's natural defenses.

Dobson CM.

Nat Struct Mol Biol. 2006 Apr;13(4):295-7. No abstract available.

PMID:
16715043
17.

Alpha-sheet: The toxic conformer in amyloid diseases?

Daggett V.

Acc Chem Res. 2006 Sep;39(9):594-602. Review.

PMID:
16981675
18.

Inhibitors of amyloid aggregation: technologies for the discovery of novel lead compounds.

Doig AJ, Stott K, Treherne JM.

Biotechnol Genet Eng Rev. 2004;21:197-212. Review. No abstract available.

PMID:
17017033
19.

Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.

Meredith SC.

Ann N Y Acad Sci. 2005 Dec;1066:181-221. Review.

PMID:
16533927
20.

Supplemental Content

Support Center